Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osilodrostat in pediatric Cushing's disease
2024-516825-30-00Phase 2Completed
- Sponsor
- Recordati SpA
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of osilodrostat in Corticotropin adenoma (ACTHoma), sponsored by Recordati SpA. Primary endpoint: Pharmacokinetic parameters of osilodrostat. Started Oct 2024; status: completed.
02
Drugs
osilodrostat
03
Conditions
Corticotropin adenoma (ACTHoma)
Beyond the preview
Go deeper on 2024-516825-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516825-30-00.